Clinical Trials Browser

Osteosarcoma

Gastric Adenocarcinoma

Ovarian Neoplasms

Ovarian Neoplasms

Advanced Biliary Tract Carcinoma

Neuroblastoma

Adenocarcinoma

Breast Neoplasms

Adenocarcinoma

Small Cell Lung Carcinoma

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Stomach Neoplasms

Stomach Neoplasms

Carcinoma, Hepatocellular

Esophageal Squamous Cell Carcinoma

Carcinoma, Hepatocellular

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

Esophageal Squamous Cell Carcinoma

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Salivary Gland Neoplasms

Liver Neoplasms

Fludzoparib" and Anti-angiogenic

Squamous Cell Carcinoma of Head and Neck

Radioactive Iodine-refractory Differentiated Thyroid Cancer

Carcinoma, Hepatocellular

Carcinoma, Non-Small-Cell Lung

Colonic Neoplasms

Adrenal Gland Neoplasms, Adrenocortical Carcinoma

Small Cell Lung Cancer Extensive Stage

Carcinoma, Hepatocellular

Small Cell Lung Cancer Limited Stage

Advanced Gastric Cancer

Stomach Neoplasms

Triple Negative Breast Neoplasms

Stomach Neoplasms

Carcinoma, Hepatocellular

Endometrial Neoplasms

Esthesioneuroblastoma, Olfactory

Neuroendocrine Tumors

Small Cell Lung Carcinoma

Carcinoma, Hepatocellular

Small Cell Lung Carcinoma

Stomach Neoplasms

HER2-negative Breast Cancer Brain Metastases

Clinical Trials

Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma

SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer

Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer

Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib

Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer

Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma: A Single-arm, Phase I/II，Multi-center, Clinical Study.

Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer

Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD

Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial

FAD-HCC-001

Adebrelimab, Apatinib & SOX for Conversion Therapy in Advanced Gastric/GEJ Cancer

SOP-XH-IRB

SHR-2554

Cocktail-001

SPARE-02

Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

ACADEMY

Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma

Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT

Adebrelimab + Apatinib in Advanced HCC Post-Systemic Therapy

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

TASK-05

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC

Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer

ICT-HCC

A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer

Neoadjuvant Therapy for Locally Advanced Colon Cancer

Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma

PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer

BIOVAS

Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma

A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer

Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer

Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping

Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma

Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC

Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach

Camrelizumab Combined with Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) As Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)

A-CAPE

A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma

Phase II Study of Adebrelimab, Chemotherapy, and Apatinib for Advanced Pulmonary Neuroendocrine Tumors

Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer

Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma

LIAES

Neoadjuvant Immunotherapy for Resectable Gastric Cancer

Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis